Use of atazanavir for improving the pharmacokinetics of raltegravir

摘要

The pharmacokinetics of HIV integrase inhibitors which are directly metabolized by UGT1A1, such as raltegravir, can be improved by co-administering with atazanavir, also known as BMS-232632 or [3S-(3R*,8'R*,9'R*,12R*)]-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenylmethyl]2,5,6,10,13-pentaazatetradecanedioic] acid, dimethyl ester.